Chris Storgard

2.2k total citations
36 papers, 1.8k citations indexed

About

Chris Storgard is a scholar working on Nephrology, Rheumatology and Molecular Biology. According to data from OpenAlex, Chris Storgard has authored 36 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Nephrology, 13 papers in Rheumatology and 10 papers in Molecular Biology. Recurrent topics in Chris Storgard's work include Gout, Hyperuricemia, Uric Acid (20 papers), Urticaria and Related Conditions (9 papers) and Case Reports on Hematomas (8 papers). Chris Storgard is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (20 papers), Urticaria and Related Conditions (9 papers) and Case Reports on Hematomas (8 papers). Chris Storgard collaborates with scholars based in United States, Spain and New Zealand. Chris Storgard's co-authors include Dwayne G. Stupack, David A. Cheresh, Xosé S. Puente, Scott Baumgartner, Maple M. Fung, Jeff Kopicko, Nihar Bhakta, Scott Adler, Simon L. Goodman and Robert I. Fox and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Chris Storgard

36 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Storgard United States	18	754	710	625	422	404	36	1.8k
Kazue Shimizu Japan	16	92 0.1×	720 1.0×	163 0.3×	151 0.4×	126 0.3×	29	1.3k
Helen Yarwood United Kingdom	19	93 0.1×	580 0.8×	201 0.3×	97 0.2×	273 0.7×	22	1.5k
Barbara Kluve‐Beckerman United States	23	202 0.3×	1.5k 2.1×	356 0.6×	114 0.3×	71 0.2×	56	1.8k
Marta Krašovec Slovenia	15	190 0.3×	318 0.4×	52 0.1×	147 0.3×	98 0.2×	17	992
Masahiko Katayama Japan	23	35 0.0×	591 0.8×	191 0.3×	175 0.4×	413 1.0×	62	1.7k
Victor Kotelianski United States	14	68 0.1×	866 1.2×	334 0.5×	36 0.1×	172 0.4×	16	1.7k
Qinlong Zheng Denmark	23	27 0.0×	457 0.6×	210 0.3×	391 0.9×	144 0.4×	46	1.6k
Satoru Shinriki Japan	24	82 0.1×	850 1.2×	146 0.2×	84 0.2×	35 0.1×	59	1.5k
Keiichi Kontani Japan	24	77 0.1×	799 1.1×	304 0.5×	65 0.2×	45 0.1×	73	2.0k

Countries citing papers authored by Chris Storgard

Since Specialization

Citations

This map shows the geographic impact of Chris Storgard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Storgard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Storgard more than expected).

Fields of papers citing papers by Chris Storgard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Storgard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Storgard. The network helps show where Chris Storgard may publish in the future.

Co-authorship network of co-authors of Chris Storgard

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Storgard. A scholar is included among the top collaborators of Chris Storgard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Storgard. Chris Storgard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maziarz, Richard T., John Edwards, James Essell, et al.. (2018). Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data. Blood. 132(Supplement 1). 2167–2167. 1 indexed citations

Tausche, Anne‐Kathrin, Rieke Alten, Nicola Dalbeth, et al.. (2017). Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Lara D. Veeken. 56(12). 2170–2178. 88 indexed citations

Morlock, Robert, Pierre Chevalier, Laura Horne, et al.. (2016). Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. Rheumatology and Therapy. 3(1). 53–75. 5 indexed citations

Nyberg, Fredrik, Laura Horne, Robert Morlock, et al.. (2016). Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis. Advances in Therapy. 33(7). 1180–1198. 14 indexed citations

Bardin, Thomas, Robert T. Keenan, Puja Khanna, et al.. (2016). Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases. 76(5). 811–820. 126 indexed citations

Pérez-Ruiz, Fernando, John S. Sundy, Jeffrey N. Miner, Matthew Cravets, & Chris Storgard. (2016). Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Annals of the Rheumatic Diseases. 75(6). 1074–1080. 72 indexed citations

Bardin, Thomas, Nicola Dalbeth, Robert Terkeltaub, et al.. (2016). THU0537 Clinical Response of Tophus and Flares To Extended Use of Lesinurad in Combination with A Xanthine Oxidase Inhibitor in Patients with Gout. Annals of the Rheumatic Diseases. 75. 386–386. 5 indexed citations

Saag, Kenneth G., David Fitzpatrick, Jeff Kopicko, et al.. (2016). Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study). Arthritis & Rheumatology. 69(1). 203–212. 135 indexed citations

Becker, Michael A., David Fitzpatrick, Hyon K. Choi, et al.. (2015). An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Seminars in Arthritis and Rheumatism. 45(2). 174–183. 90 indexed citations

10.

Khanna, Puja, Dinesh Khanna, Chris Storgard, Scott Baumgartner, & Robert Morlock. (2015). A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgraduate Medicine. 128(1). 34–40. 28 indexed citations

11.

Shen, Zancong, V. Hingorani, Kimberly J. Manhard, et al.. (2015). Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Design Development and Therapy. 9. 3423–3423. 43 indexed citations

12.

Bardin, Thomas, Robert T. Keenan, Puja Khanna, et al.. (2015). FRI0333 Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination with Allopurinol: Results from a Phase III Study in Gout Patients Having an Inadequate Response to Standard of Care (Clear 2). Annals of the Rheumatic Diseases. 74. 545–545. 8 indexed citations

13.

Saif, Muhammad Wasif, Charles Erlichman, Tomislav Dragovich, et al.. (2013). Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 71(5). 1345–1355. 25 indexed citations

14.

Hong, David S., Rabih Said, Gerald S. Falchook, et al.. (2013). Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. Clinical Cancer Research. 19(17). 4824–4831. 20 indexed citations

15.

Khanna, Dhanita, Puja Khanna, Chris Storgard, Scott Baumgartner, & Robert Morlock. (2013). SAT0384 Patients that Continue to Flare Despite Reaching Eular/ ACR Recommended Serum Urate Target. Annals of the Rheumatic Diseases. 72. A713–A714. 1 indexed citations

16.

Hoff, Daniel D. Von, M. Beeram, Januario E. Castro, et al.. (2007). Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor. Molecular Cancer Therapeutics. 6. 1 indexed citations

17.

Rosen, Lee S., David S. Hong, Linnea Chap, et al.. (2007). First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3522–3522. 9 indexed citations

18.

Storgard, Chris, David Mikolon, & Dwayne G. Stupack. (2004). Angiogenesis Assays in the Chick CAM. Humana Press eBooks. 294. 123–136. 47 indexed citations

19.

Storgard, Chris, Dwayne G. Stupack, Alfred Jonczyk, et al.. (1999). Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. Journal of Clinical Investigation. 103(1). 47–54. 266 indexed citations

20.

Conly, John, et al.. (1990). Herpes Labialis in Parturients Receiving Epidural Morphine Following Cesarean Section. Anesthesiology. 73(2). 208–213. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact